US Evaluation of Topical Hemostatic Agents in Post-Thyroidectomy

Cancers (Basel). 2023 May 7;15(9):2644. doi: 10.3390/cancers15092644.

Abstract

Background: the aim of this study was to describe the ultrasound appearance of topical hemostatics after thyroidectomy.

Methods: we enrolled 84 patients who were undergoing thyroid surgery and were treated with two types of topical hemostats, 49 with an absorbable hemostat of oxidized regenerated cellulose (Oxitamp®) and 35 with a fibrin glue-based hemostat (Tisseel®). All patients were examined using B-mode ultrasound.

Results: In 39 patients of the first group (approximately 80%), a hemostatic residue was detected and in some cases confused with a native gland residue, or with cancer recurrence in oncological patients. No residue was detected in patients in the second group. The main ultrasound characteristics of the tampon were analyzed and arranged according to predefined patterns, and suggestions to recognize it and avoid wrong diagnoses were provided. A part of the group of patients with tampon residue was re-evaluated after 6-12 months, ensuring that the swab remained for months after the maximum resorption time declared by the manufacturer.

Conclusions: with equal hemostatic effectiveness, the fibrin glue pad is more favorable in the ultrasound follow-up because it creates reduced surgical outcomes. It is also important to know and recognize the ultrasound characteristics of oxidized cellulose-based hemostats in order to reduce the number of diagnostic errors and inappropriate diagnostic investigations.

Keywords: Oxitamp®; Tisseel®; radiological follow-up; thyroidectomy; topical hemostatic agents; ultrasound.

Grants and funding

This research received no external funding.